Stephen Stamp joins board at Eusa Pharma

pharmafile | September 7, 2010 | Appointment | Sales and Marketing Eusa Pharma, appointment, sales and marketing 

Transatlantic specialty company Eusa Pharma has appointed Stephen Stamp to its board as an independent non-executive director.

Stephen has previously held board-level roles at Xanodyne Pharmaceuticals and Shire Pharmaceuticals, and was most recently chief financial officer at K-V Pharmaceutical Company.

Commenting on his appointment, Stephen said, “Having witnessed EUSA’s impressive growth, I am excited to be helping the company achieve its ambitious plans.

Advertisement

“Having already built a robust commercial infrastructure in the US and Europe, and a wider global distribution network, I believe EUSA is well placed for future success, and I welcome the opportunity to be part of the company’s continued rapid development.”

Eusa is jointly based in Oxford, UK and Langhorne, PA, in the US and focuses on in-licensing, developing and marketing late-stage oncology, pain control and critical care products.

Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

shutterstock_38078521

EUSA Pharma gets FDA green light to evaluate IL-6 inhibitor siltuximab in COVID-19 patients

Efforts push on to discover an effective treatment for COVID-19 in more than 100 different …

eusa

EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …

The Gateway to Local Adoption Series

Latest content